Transformation of a previously diagnosed diffuse large B‐cell lymphoma to plasmablastic lymphoma

Marini, Carolina; Baldaia, Helena; Trigo, Fernanda; Castillo, Jorge J.

doi:10.1002/ajh.24375

Cited by 5 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PbL can be diagnosed as the final event (transformation) of an indolent lymphoproliferative syndrome 20. Cases after an acute lymphoblastic leukemia or DLBCL have also been described 20,24…”

Section: Introductionmentioning

confidence: 99%

Plasmablastic lymphoma: current perspectives

López¹,

Abrisqueta²

2018

BLCTT

111

View full text Add to dashboard Cite

Plasmablastic lymphoma (PbL) is a rare and aggressive B-cell malignancy with large neoplastic cells, most of them resembling plasmablasts that have a CD20-negative phenotype. Although initially described as being associated with HIV, over the years it has also been identified in patients with solid organ transplant and immunocompetent patients. Little is known about molecular basis that drives PbL, and still its diagnosis remains challenging given its rarity. However, proper recognition of its clinical characteristics, localization, and morphological features can establish a correct diagnosis of PbL within the spectrum of CD20-negative large B-cell lymphomas (LBCLs). PbL is characterized by CD20 and PAX5 negativity together with the expression of CD38, CD138, MUM1/IRF4, Blimp1, and XBP1 plasmacytic differentiation markers. It is usually associated with Epstein–Barr virus infections, and MYC gene rearrangements. PbL should be carefully differentiated from other CD20-negative B-cell neoplasms, ie, primary effusion lymphoma, anaplastic lymphoma kinase-positive (ALK) large B-cell lymphoma, and LBCL in human herpesvirus 8-associated multicentric Castleman disease. Despite our improved understanding of this disease, its prognosis remains dismal with short overall survival. There is no standard of care for this entity. Several chemotherapy combinations have been used with hardly any differences on its outcome. Thus, new approaches with the addition of novel molecules are needed to overcome its poor prognosis. Our current understanding and knowledge of PbL relies primarily on case reports and small case series. In this review, we revise through an extensive literature search, the clinical and biological characteristics of this entity, and the potential therapeutic options.

show abstract

Section: Introductionmentioning

confidence: 99%

Plasmablastic lymphoma: current perspectives

López¹,

Abrisqueta²

2018

BLCTT

111

View full text Add to dashboard Cite

show abstract

“…2 In contrast with PCMs which have well-established treatment options, PT often leads to rapid clinical deterioration in most cases despite aggressive treatments. 3,16 Our patient's PT-PCM lesions presented while on therapy, despite good treatment response as assessed by serologic studies, including the levels of IgA and light chains. This pattern has been noted in other reports as well.…”

Section: Discussionmentioning

confidence: 89%

“…This pattern has been noted in other reports as well. 3,16 The mean survival is usually less than 2 years, which tends to be further reduced in extramedullary cases. 1,3,13 No standard chemotherapy regimen exists for PT-PCM.…”

Section: Discussionmentioning

confidence: 99%

Scattered Violaceous Papules on the Trunk of an Adult Female: Answer

Hobbs

Lee

Kozak

et al. 2022

The American Journal of Dermatopathology

View full text Add to dashboard Cite

“…The clonal relation between PBL and low-grade lymphoma has been demonstrated in a case series [ 16 ]. Marini et al [ 17 ] reported a case with transformed PBL from previously diagnosed DLBCL, but they did not show a clonal relation between the two tumors. To the best of our knowledge, this is the first case that demonstrates the simultaneous occurrence of clonally related PBL with DLBCL.…”

Section: Discussionmentioning

confidence: 99%

Clonally Related Plasmablastic Lymphoma Simultaneously Occurring with Diffuse Large B-Cell Lymphoma

Hashimoto

Ueda

Hiraiwa

et al. 2020

Case Reports in Hematology

View full text Add to dashboard Cite

Plasmablastic lymphoma (PBL) is a rare aggressive lymphoma. Although it was first described in HIV- (human immunodeficiency virus-) infected patients, PBL has been diagnosed in patients with other immunodeficiencies as well as in immunocompetent patients. PBL immunohistochemically expresses plasmacytic markers and lacks pan B-cell markers. The cells of origin of PBL are considered to be plasmablasts. MYC gene rearrangement and MYC overexpression are frequently found in PBL, but the pathogenesis of PBL is yet to be elucidated. Here, we report a case of composite lymphoma of PBL and diffuse large B-cell lymphoma (DLBCL); that is, PBL in the urinary bladder and DLBCL in the nasal cavity occurred simultaneously. We extracted DNA from the two lymphomas for polymerase chain reaction and sequenced the amplified immunoglobulin heavy variable genes and the complementarity-determining region- (CDR-) 3. The sequence of the CDR3 region of both tumors matched. MYC rearrangement was found in the bladder tumor but not in the nasal tumor. The patient was treated with R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone), and durable remission had been obtained. The results of the DNA analysis indicated that both PBL and DLBCL emerged from common postgerminal B cells. This case may help to elucidate the pathogenesis of PBL.

show abstract

Transformation of a previously diagnosed diffuse large B‐cell lymphoma to plasmablastic lymphoma

Cited by 5 publications

References 6 publications

Plasmablastic lymphoma: current perspectives

Plasmablastic lymphoma: current perspectives

Scattered Violaceous Papules on the Trunk of an Adult Female: Answer

Clonally Related Plasmablastic Lymphoma Simultaneously Occurring with Diffuse Large B-Cell Lymphoma

Contact Info

Product

Resources

About